How meningiomas change over time and new treatment targets
Official title: Project 2: Biological mechanisms and therapeutic vulnerabilities underlying meningioma evolution and heterogeneity
Funded at University of California, San Francisco · NIH-11192771 · Data updated 2026-11-12
This project looks for molecular signs that predict which meningiomas will come back and finds drug targets to help people with aggressive or recurrent tumors.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2007 |
| Project end | August 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $480,584 |
| NIH project number | 5P01CA118816-17 |
| Project ID | NIH-11192771 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with a diagnosis of meningioma—especially those having surgery, with recurrent tumors, or with WHO grade 2–3 disease—are the most likely candidates for tests or trials from this project.
✕Less likely to help
People without meningioma, without available tumor tissue, or whose tumors are already well controlled may not see direct benefit from this work.
What this research studies
Researchers analyzed tumor samples from more than 2,000 meningiomas collected across many hospitals using DNA methylation, gene expression, and other molecular tests. They identified molecular groups and a gene expression marker that predict which tumors are more likely to recur and which may respond to radiotherapy or cell-cycle blocking drugs. This work aims to help doctors decide who needs extra treatment after surgery and to point to drugs that might work for aggressive tumors. The team is working to move these molecular tests into clinical guidelines and trials so patients can benefit from more personalized care.
Why it matters
Potential benefit: Could allow more accurate prediction of tumor recurrence and direct patients to treatments more likely to work for their tumor.
How similar studies have gone: Other tumor profiling efforts have improved classification and treatment selection in brain tumors, and initial data from this project already show promise for predicting meningioma outcomes and therapy vulnerabilities.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Raleigh, David R — University of California, San Francisco
- Study coordinator: Raleigh, David R
Related research
Other NIH-funded projects on the same topics.
-
Meningioma biology and new therapies guided by molecular profiling
A large, multi-institution study is exploring how meningiomas grow and respond to treatment, using advanced molecular profiling to find safer, more effective ways to manage them.
-
Biomarker-based guidance to predict meningioma outcomes and radiotherapy response
A gene-based test is being developed to help predict how meningioma tumors will behave and how patients may respond to radiotherapy.
-
Meningioma radiotherapy response: understanding gene clues and how to tailor treatment
A short research project will study why some meningioma tumors respond differently to radiotherapy by looking at gene activity and how it affects treatment outcomes.
-
Genomic and biochemical clues behind meningioma race differences and outcomes
This grant aims to uncover biological and environmental factors that cause differences in meningioma occurrence and treatment results across racial groups, with the goal of improving care for patients affected by this brain tumor.
-
How the MN1 protein drives aggressive acute myeloid leukemia
This project looks at how the MN1 protein and its partner BAF complex keep leukemia genes active in people with acute myeloid leukemia to reveal new treatment targets.
-
Finding new ways to treat meningioma brain tumors
This project looks for new medicine targets to help patients with meningioma, a common type of brain tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.